
reViral hires non-executive director
pharmafile | April 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | reviral, schinazi
Antiviral drug firm reViral has appointed Professor Raymond Schinazi as a non-executive director.
Schinazi has had a long and prestigious career in the industry having founded several biotech companies including Pharmasset, where he chaired the board and directed the scientific research leading to the discovery of promising hepatitis C treatment Sovaldi.
Ken Powell, chairman and founder of reViral says: “We are very pleased to have attracted someone of Ray’s experience and prestige to reViral. A world leader in nucleoside chemistry and biology, Ray’s discoveries have made a tangible impact on the quality of life and welfare of society. His remarkable accomplishments and wealth of experience will be integral to reViral.”
Newly-appointed Schinazi adds: “I look forward to working with the proven management team and am excited by the company’s highly promising programme and pipeline, as it expands into areas of high unmet need.”






